Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMVWZN1)

Drug Name

F-200 Drug Info

Synonyms

Eos-200-F; Anti-alpha-5/beta-1 integrin Ab Fragment, PDL; Anti-alpha-5/beta-1 integrin Fab, PDL; Anti-alpha-5/beta-1 integrin Fab, Protein Design Labs

Indication

Disease Entry	ICD 11	Status	REF
Ocular disease	1F00.1Z	Terminated	[1]

Cross-matching ID

PubChem CID: 16660135
TTD Drug ID: DMVWZN1

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Integrin alpha-5/beta-1 (ITGA5/B1)	TTH4QIS	ITA5_HUMAN-ITB1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Integrin alpha-5/beta-1 (ITGA5/B1)	DTT	ITGA5-ITGB1	3.935	4.833	4.278	4.661

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Ocular disease

ICD Disease Classification

1F00.1Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Integrin alpha-5/beta-1 (ITGA5/B1)	DTT	ITGA5-ITGB1	2.88E-04	0.22	1.11

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018439)
2	US patent application no. 8,541,413, Sustained release eye drop formulations.